Factors associated with achieving complete response in patients older than 65 years diagnosed with diffuse large b-cell lymphoma in first-line therapy. report from a tertiary center in Mexico city

Abstract Introduction: The prevalence of diffuse large B-cell lymphoma (DLBCL) in the geriatric population has increased in recent decades. The primary objectives in this population are to achieve complete response in first-line therapy (CR1), improve quality of life, and overall survival (OS) with minimal adverse effects.Objective: To identify the variables that helped patients achieve complete response in conjunction with the chemotherapy regimen.Methodology: Retrospective, observational, and descriptive study. Patients over 65 years with a diagnosis (Dx) of DLBCL treated at the National Cancer Institute from January 2018 to December 2023 were included. Sociodemographic characteristics were collected, potential associated factors (clinical, biochemical, and social) and clinical outcome were recorded, with achievement of CR1 and OS using Cox regression.Results: A total of 253 patients were identified, with a predominance of women (58%), age of 73 years (range, 65–94 years), and approximately 70% with an adverse prognosis (RIPI). The most commonly used treatment was R-CHOP (59%), followed by R-miniCHOP (17%). Complete response was 53%, and the median overall survival was 72 months (range, 62–82 months). Factors associated with a higher CR1 rate were: having a support network (OR=2.603, p=0.017), admission to the Intensive Care Unit (ICU) (OR=3.583, p=0.008), and normal leukocyte count at diagnosis (OR=1.011, p=0.041). Factors that improved OS were: support from palliative care services (HR=4.73, p=0.01) and ICU (HR=13.95, p=0.001), CR1 (HR=1.890, p=0.001), dose (HR=2.159, p=0.08), and consolidation radiotherapy (HR=4.77, p=0.027).Conclusions: It is important to identify factors associated with improved CR1 and OS in this age group. However, the information obtained through prospective studies needs to be confirmed and strengthened.

Authors

Institutions

Publication Details

Journal
Blood
Published
2025-11-03
DOI
https://doi.org/10.1182/blood-2025-7183
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Factors associated with achieving complete response in patients older than 65 years diagnosed with diffuse large b-cell lymphoma in first-line therapy. report from a tertiary center in Mexico city

J. H. Carneiro de Araújo, Lucy T. González, Silvia Rivas, C. Medrano et al.
Blood
Lymphoma Diagnosis and Treatment
article

Factors associated with achieving complete response in patients older than 65 years diagnosed with diffuse large b-cell lymphoma in first-line therapy. report from a tertiary center in Mexico city

J. H. Carneiro de Araújo, Lucy T. González, Silvia Rivas, C. Medrano, Miguel Ramos, Nidia Zapata
article en

Abstract

Abstract Introduction: The prevalence of diffuse large B-cell lymphoma (DLBCL) in the geriatric population has increased in recent decades. The primary objectives in this population are to achieve complete response in first-line therapy (CR1), improve quality of life, and overall survival (OS) with minimal adverse effects.Objective: To identify the variables that helped patients achieve complete response in conjunction with the chemotherapy regimen.Methodology: Retrospective, observational, and descriptive study. Patients over 65 years with a diagnosis (Dx) of DLBCL treated at the National Cancer Institute from January 2018 to December 2023 were included. Sociodemographic characteristics were collected, potential associated factors (clinical, biochemical, and social) and clinical outcome were recorded, with achievement of CR1 and OS using Cox regression.Results: A total of 253 patients were identified, with a predominance of women (58%), age of 73 years (range, 65–94 years), and approximately 70% with an adverse prognosis (RIPI). The most commonly used treatment was R-CHOP (59%), followed by R-miniCHOP (17%). Complete response was 53%, and the median overall survival was 72 months (range, 62–82 months). Factors associated with a higher CR1 rate were: having a support network (OR=2.603, p=0.017), admission to the Intensive Care Unit (ICU) (OR=3.583, p=0.008), and normal leukocyte count at diagnosis (OR=1.011, p=0.041). Factors that improved OS were: support from palliative care services (HR=4.73, p=0.01) and ICU (HR=13.95, p=0.001), CR1 (HR=1.890, p=0.001), dose (HR=2.159, p=0.08), and consolidation radiotherapy (HR=4.77, p=0.027).Conclusions: It is important to identify factors associated with improved CR1 and OS in this age group. However, the information obtained through prospective studies needs to be confirmed and strengthened.

BloodVol. 146(Supplement 1)
Cemex (Mexico) (MX), Instituto Nacional de Cancerología (MX), Pemex (Mexico) (MX), Institute for Social Security and Services for State Workers (MX)
Openalex Percentile: Top 46%
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.